Weight loss with glucagon-like peptide-1 receptor agonists in Bardet-Biedl syndrome.

Shawg Ganawa, Smrithi Hema Santhosh, Lucy Parry, Akheel A Syed

Clinical obesity 2022 Aug 06

filter terms:

Bardet-Biedl syndrome (BBS) is a rare genetic condition, characterized by ciliary protein dysfunction, leading to multi-organ damage. People with BBS can develop early-onset severe obesity and associated problems including the metabolic syndrome, type 2 diabetes and coronary heart disease. Weight management can be challenging with the lack of effective medical therapies so far. We report a patient with BBS who underwent successful weight reduction through the use of glucagon-like peptide-1 receptor agonists. © 2022 The Authors. Clinical Obesity published by John Wiley & Sons Ltd on behalf of World Obesity Federation.

Citation

Shawg Ganawa, Smrithi Hema Santhosh, Lucy Parry, Akheel A Syed. Weight loss with glucagon-like peptide-1 receptor agonists in Bardet-Biedl syndrome. Clinical obesity. 2022 Aug 06;12(5):e12546